Blood Test May Predict Alzheimer-Related Cognitive Decline Years Ahead, Mayo Clinic Study Finds

A blood test that detects a protein linked to Alzheimer's disease could help predict whether older adults will develop cognitive decline within five to 10 years, according to a new Mayo Clinic study published in JAMA Neurology.
The study looked at levels of phosphorylated tau 217, or p-tau217, in 2,178 cognitively unimpaired adults ranging in age from 60 to 90.
Alongside p-tau217, the researchers considered age, gender and whether participants carried the APOE ε4 genetic variant, which is associated with Alzheimer's risk.
The participants were drawn from the Mayo Clinic Study of Aging and the Alzheimer's Disease Neuroimaging Initiative, and underwent blood biomarker testing, genetic testing and multiple cognitive assessments.
The study found that APOE ε4 had a modest association with risk after accounting for p-tau217, while older age was associated with greater risk.
At the same elevated p-tau217 level, a 65-year-old faced a 6 percent estimated five-year risk of mild cognitive impairment, compared with a 37 percent risk for an 85-year-old.
Senior author Clifford Jack Jr., M.D., a Mayo Clinic neuroradiologist, noted that Alzheimer's disease is marked by plaques and tangles that accumulate in the brain. He told Fox News Digital that the test tells, just by taking a blood sample, whether someone has that pathology in the brain, and that higher levels are associated with a greater risk of progressing from normal cognition to impairment.
Detecting p-tau217 in blood may be less invasive and potentially more scalable than using PET scans to measure amyloid burden, a hallmark of Alzheimer's disease that is associated with future cognitive impairment, according to the researchers.
The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology, first author Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher, said in a news release.
If investigational treatments are found to be effective at preventing or delaying cognitive decline, this blood test could take on greater significance, according to the researchers. Jack noted that if preventive treatments become available, this kind of information could help patients and clinicians have more informed conversations about the potential benefits and risks of treatment.
The researchers also noted the study's limitations. The risk estimates were developed in the Mayo Clinic Study of Aging, which is drawn from a specific geographical area, and Jack said the older population in southeast Minnesota is not representative of the entire United States. While the methods could be applied to other populations, the findings need to be replicated outside the region, he said.
The risk prediction model is not yet ready for routine screening of people without cognitive symptoms, according to the research team. Jack told Fox News Digital there is no treatment approved for people who are asymptomatic but have the disease in the brain, so the test results would not change medical management. The study also does not establish that routine blood testing prevents dementia or improves clinical outcomes, and Jack added that many elderly people who have the pathology in the brain at lower levels will never develop symptoms in their lifetime.



